title: [Relationship between phenomenon of acquired activated protein C resistance and antiphospholipid antibodies in patients with systemic lupus erythematosus].
abstract: OBJECTIVE
  To determine the occurrence of activated protein C resistance (APCR), to identify APCR is associated with thrombotic events (TEs), and acquired APCR is associated with the presence of antiphospholipid antibodies (APLAs) in 30 patients with systemic lupus erythematosus (SLE).
  
  
  METHODS
  Laboratory tests included dilute Russell's viper venom time assay for LA (dRVVT-LA), ELISA assay for ACL, APC sensitivity ratio, and factor V Leiden were detected by PCR-Mnl/I digestion.
  
  
  RESULTS
  Acquired APCR was presented in 14(46.67%) of 30 patients. Factor V Leiden was not found in any patients. The incidence of TEs in the APCR-positive patients was significantly higher than that in the APCR-negative patients (42.85% vs 6.25%, P < 0.05). The incidence of TEs in the LA-positive patients was also significantly higher than that in the LA-negative patients (50% vs 11.1%, P < 0.05).
  
  
  CONCLUSIONS
  The presence of either APCR or LAs is associated with one of the risk factors of TEs (P < 0.05). There is not a significant interaction between APCR and LAs in the association with TEs. Acquired APCR may not reflect the interference of LAs with the protein C pathway which may represent a mechanism of LA-associated TEs.
authors.affiliation: Department of Clinical Haematology, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Hu
authors.forename: F P
authors.initials: FP
authors.lastname: Chen
authors.forename: Q Z
authors.initials: QZ
authors.lastname: Xie
mesh_terms: D020016:Activated Protein C Resistance / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D002648:Child; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D012307:Risk Factors; D020246:Venous Thrombosis / Q000209:etiology / Q000276:immunology / Q000378:metabolism
chemical_list: D017152:Antibodies, Antiphospholipid; D008775:Methylprednisolone